PT-141
A melanocortin agonist that acts on the brain to influence sexual desire. As bremelanotide (Vyleesi) it is FDA-approved for hypoactive sexual desire disorder in premenopausal women; broader use is off-label.
Quick take
- What it is: a melanocortin-receptor agonist that acts centrally on pathways involved in sexual desire, derived from the melanotan peptide family.
- What people use it for: the approved use is low sexual desire (HSDD) in premenopausal women; it is also used off-label by others.
- What we actually know: controlled trials support a modest benefit for HSDD; data outside that population are more limited.
- Status: FDA-approved as Vyleesi for HSDD in premenopausal women; other uses are off-label.
What it is
PT-141, known as bremelanotide, is a peptide that acts on the brain’s melanocortin system to influence sexual desire and arousal. It was developed from the same melanocortin peptide family as the melanotan compounds, but selected for its effects on sexual function. As the approved product Vyleesi, it is supplied as a subcutaneous auto-injector.1
Unlike many peptides discussed online, PT-141 has a clear, narrow approved use and a body of controlled clinical-trial evidence behind that use.
How it works
PT-141 is a melanocortin-receptor agonist that is thought to act centrally, particularly via MC4R in the brain, on neural pathways involved in sexual motivation and arousal. This is a fundamentally different mechanism from PDE5 inhibitors such as sildenafil, which act on genital blood flow rather than central desire.1,2
What the evidence shows
Animal studies
Animal work on melanocortin agonists demonstrated effects on sexual behaviour mediated by central MC4R signalling, providing the rationale for testing in people.2
Human studies
Bremelanotide was evaluated in randomised, placebo-controlled trials (the RECONNECT studies) in premenopausal women with hypoactive sexual desire disorder. These trials showed a modest but statistically significant improvement in measures of desire and reduction in associated distress, which supported FDA approval.3 Evidence in other populations, such as men or postmenopausal women, is more limited.
Dosages reported in the literature
Informational only. The figures below describe the approved product and reported use. They are not a recommendation or a prescription. Appropriate use, if any, should be determined by a qualified healthcare professional.
| Setting | Route | Reported range |
|---|---|---|
| HSDD (approved product) | Subcutaneous injection | 1.75 mg as needed, ≥45 min before activity; max one dose/24 h and limited doses/month, per label |
| Off-label use | Subcutaneous injection | Variable; not standardised outside the approved indication |
Only the approved on-label dosing reflects studied use. Off-label protocols are not standardised.
Safety & side effects
The most common adverse effect is nausea, especially with the first dose. Other reported effects include flushing, headache and injection-site reactions. PT-141 can cause a transient increase in blood pressure with a small decrease in heart rate, so it is generally avoided in people with uncontrolled high blood pressure or significant cardiovascular disease.3,4 Repeated use can cause skin and facial darkening (hyperpigmentation), consistent with its melanocortin activity.
As with any peptide, products bought outside the regulated supply chain carry additional purity and dosing concerns.
Legal & regulatory status
Bremelanotide (Vyleesi) is FDA-approved for acquired, generalised hypoactive sexual desire disorder in premenopausal women.1 That approval is specific to that population; use in men or other groups is off-label. Unregulated “PT-141” products sold online are not the approved drug. Rules differ by country and change over time.
References
- U.S. Food and Drug Administration. VYLEESI (bremelanotide injection), for subcutaneous use — Full Prescribing Information. Initial U.S. Approval: 2019. NDA 210557. accessdata.fda.gov. [accessdata.fda.gov]
- Comninos AN, Hansen MS, Courtney A, et al. Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder. J Clin Invest. 2022;132(19):e152341. doi:10.1172/JCI152341. [PMID 36189794, doi:10.1172/JCI152341]
- Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. doi:10.1097/AOG.0000000000003500. [PMID 31599840, doi:10.1097/AOG.0000000000003500]
- Clayton AH, Kingsberg SA, Portman D, Sadiq A, Krop J, Jordan R, Lucas J, Simon JA. Safety Profile of Bremelanotide Across the Clinical Development Program. J Womens Health (Larchmt). 2022;31(2):171-182. doi:10.1089/jwh.2021.0191. [PMID 35147466, doi:10.1089/jwh.2021.0191]